Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate.

Next Previous
X
Search
Trial Profile

A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms AGREE
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 09 Nov 2021 Results (n=2087) of pooled analysis from 4 Randomized Controlled Trials (NCT00122382, NCT00929864, NCT01142726 and NCT02504268) assessing clinical outcomes among patients with SPEAR and non-SPEAR to understand the differential treatment impact of ABA on each ACR core measure, presented at the ACR Convergence 2021
    • 09 Nov 2021 Results of pooled analysis from NCT00122382, NCT00929864, NCT01142726 and NCT02504268; comparing clinical outcomes of RA patients with enriched autoantibody biomarkers and early disease stage (SPEAR) to non-SPEAR, presented at the ACR Convergence 2021
    • 05 Jun 2021 Results of post-hoc pooled analysis (n=2087) assessing enhanced efficacy of abatacept among patients with enriched autoantibody biomarkers and early disease stage from the eAMPLE trial retrospectively to historic abatacept randomized controlled trials (from four early-RA ABA trials (AGREE [NCT00122382], AMPLE [NCT00929864], AVERT [NCT01142726], AVERT-2 [NCT02504268]), presented at the 22nd Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top